Phytases are the most valuable enzyme in virtually all monogastric formulations, but their value is subject to the interaction with many variables, which are not well represented in the literature. Care must be taken, therefore, in implementation of its matrix. Test conditions employed are often not vigorous enough to detect differences between different doses or products, and as a result, decisions based on such results may not reflect the true value of each dose or product. Continuous application of a phytase over a long period will undoubtedly result in some conditions where the phytase delivers more and some when it delivers less than expected. It is the latter of which the end user should be wary and take steps when reviewing the data available to minimize the likelihood of such events taking place.
No takes yet. Share an insight, caveat, or question.
Bedford et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: